The 3.6 trillion won U.S. market has begun in earnest.

Celltrion announced on the 27th that it has obtained a license from the Food and Drug Administration (FDA) to sell the Avastin biosimilar Vegzelma.

Vegzelma has been approved for Avastin's indications, including metastatic direct bowel cancer, non-small cell lung cancer, metastatic renal cell cancer, cervical cancer, epithelial ovarian cancer, ovarian cancer, ovary cancer (uterine cancer), primary peritoneal cancer, and circulating glioblastoma. Since August, Celltrion has sequentially obtained sales licenses for Vegzelma from regulators in major global countries such as Europe, the United Kingdom, and Japan.

Chon, Seung-Hyun(1000@dailypharm.com)